Literature DB >> 21526158

Association between the SERPING1 gene and age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese.

Isao Nakata1, Kenji Yamashiro, Ryo Yamada, Norimoto Gotoh, Hideo Nakanishi, Hisako Hayashi, Akitaka Tsujikawa, Atsushi Otani, Masaaki Saito, Tomohiro Iida, Akio Oishi, Keitaro Matsuo, Kazuo Tajima, Fumihiko Matsuda, Nagahisa Yoshimura.   

Abstract

PURPOSE: Recently, a complement component 1 inhibitor (SERPING1) gene polymorphism was identified as a novel risk factor for age-related macular degeneration (AMD) in Caucasians. We aimed to investigate whether variations in SERPING1 are associated with typical AMD or with polypoidal choroidal vasculopathy (PCV) in a Japanese population.
METHODS: We performed a case-control study in a group of Japanese patients with typical AMD (n = 401) or PCV (n = 510) and in 2 independent control groups--336 cataract patients without age-related maculopathy and 1,194 healthy Japanese individuals. Differences in the observed genotypic distribution between the case and control groups were tested using chi-square test for trend. Age and gender were adjusted using logistic regression analysis.
RESULTS: We targeted rs2511989 as the haplotype-tagging single nucleotide polymorphism (SNP) for the SERPING1 gene, which was reported to be associated with the risk of AMD in Caucasians. Although we compared the genotypic distributions of rs2511989 in typical AMD and PCV patients against 2 independent control groups (cataract patients and healthy Japanese individuals), SERPING1 rs2511989 was not significantly associated with typical AMD (P = 0.932 and 0.513, respectively) or PCV (P = 0.505 and 0.141, respectively). After correction for age and gender differences based on a logistic regression model, the difference in genotypic distributions remained insignificant (P>0.05). Our sample size had a statistical power of more than 90% to detect an association of a risk allele with an odds ratio reported in the original studies for rs2511989 for developing AMD.
CONCLUSIONS: In the present study, we could not replicate the reported association between SERPING1 and either neovascular AMD or PCV in a Japanese population; thus, the results suggest that SERPING1 does not play a significant role in the risk of developing AMD or PCV in Japanese.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21526158      PMCID: PMC3079757          DOI: 10.1371/journal.pone.0019108

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Age-related macular degeneration (AMD) is the leading cause of visual loss in the developed world [1]. Several genes have been reported to be associated with this disease, including complement factor H [2]–[4] and the age-related maculopathy susceptibility 2/HtrA serine peptidase 1 (ARMS2/HTRA1) region [5], [6], and subsequent studies have replicated the association between susceptibility genes and the development of AMD using a different ethnic cohort [7]–[10]. Inner choroidal vascular networks that terminate in polypoidal lesions are defined as polypoidal choroidal vasculopathy (PCV), and are typically visualized by indocyanine green angiography [11]. Whether PCV represents a subtype of neovascular AMD remains controversial; moreover, whether this condition represents inner choroidal vascular abnormalities or is a variety of choroidal neovascularization remains unknown [12]. Previous studies identified several genes that contribute to the development of PCV; however, almost all reported genetic risk factors for PCV are the same as for AMD [13]–[15], and this suggests that AMD and PCV share, at least in part, the same genetic background. Studies in cohorts from both the United Kingdom and the United States have shown that the complement component 1 inhibitor (SERPING1) gene is positively associated with AMD [16]. However, another study in a larger cohort (n = 7723 and 2327) which involved the same population could not replicate the finding of the previous study [17], [18]. Recently, Lee et al. have shown that SERPING1 is positively associated with AMD in Caucasians [19], but whether this gene is truly associated with AMD remains controversial. Furthermore, the association of SERPING1 with AMD has been evaluated also in Asians. Lu et al. examined the association in 194 AMD patients and 285 controls and reported that SERPING1 is not associated with AMD in the Chinese population [20]. The association between PCV and SERPING1 has also been evaluated in a smaller Chinese cohort (118 patients and 115 controls), also with negative findings [21]. So far, all Asian studies for SERPING1 did use smaller cohorts than those of original studies and not consider their statistical power. For evaluating the true gene-disease association, it would be helpful to replicate the positive association reported in previous studies using a different ethnic cohort. The aim of this study, which involved a relatively large number of participants, was to investigate whether the SERPING1 gene variants are associated with typical AMD or PCV in a Japanese population.

Materials and Methods

All procedures in this study adhered to the tenets of the Declaration of Helsinki. This study was approved by the Ethics Committee of each institute involved (Kyoto University Graduate School and Faculty of Medicine, Ethics Committee, the Ethical Committee of Fukushima Medical University, the Ethical Committee of Kobe City Medical Center General Hospital, the Ethical Committee of Ozaki Eye Hospital, the Ethical Committee of the Otsu Red Cross Hospital, the Ethical Committee of Nagahama City Hospital, and the Ethical Committee at Aichi Cancer Center). All of the patients were fully informed about the purpose and procedures of this study, and written consent was obtained from each. In this study, 401 patients with typical AMD and 510 patients with PCV were recruited from the Department of Ophthalmology at Kyoto University Hospital, Fukushima Medical University Hospital, and Kobe City Medical Center General Hospital. The control group included 2 populations: (1) 336 individuals who underwent cataract surgery and had no age-related maculopathy (ARM) (Control 1) were recruited from the Department of Ophthalmology, Kyoto University Hospital, Ozaki Eye Hospital, Japanese Red Cross Otsu Hospital, and Nagahama City Hospital; and (2) 1194 healthy individuals who were recruited from the Aichi Cancer Center Research Institute as the general population control (Control 2). AMD and ARM were defined according to the International Classification System for ARM and AMD [22]. The diagnosis of PCV was based on indocyanine green angiography, which showed a branching vascular network that terminated in polypoidal swelling. Typical AMD were late AMD which showed classic choroidal neovascularization (CNV), occult CNV, or both. All diagnoses were made by 3 retina specialists (K.Y., A.T., and A.O.); a fourth specialist (N.Y.) was consulted when the subtype classification could not be decided on by the initial 3 reviewers. All of the subjects were unrelated and were of the Japanese descent. Genomic DNAs were isolated from the peripheral blood of the subjects by using a DNA extraction kit (QuickGene-610L, Fujifilm, Minato, Tokyo, Japan). The samples of all the patients with typical AMD and PCV and of cataract patients were genotyped using a Taqman single nucleotide polymorphism (SNP) assay with the ABI PRISM 7700 system (Applied Biosystems, Foster City, CA). The individuals recruited from the Aichi Cancer Center Research Institute were genotyped using Illumina Human-Hap 610 chips (Illumina Inc., San Diego, CA). Linkage disequilibrium (LD) structures across the SERPING1 gene were compared between the Caucasian and Japanese populations, using genotype data retrieved from the HapMap CEU and JPT data sets [23]. The retrieved data were loaded into Haploview to estimate LD parameters and to identify haplotype blocks [24]. Deviations in genotype distributions from the Hardy–Weinberg equilibrium (HWE) were assessed using the HWE exact test. Statistical analyses for differences in the observed genotypic distribution were performed by the chi square test for trend; logistic regression analysis was performed for age and gender adjustments. The statistical power calculation was performed using QUANTO version 1.2 [25]. P values less than 0.05 were considered statistically significant.

Results

The demographic details of the study population are presented in Table 1. Because all SNPs of the SERPING1 gene are in the same haplotype block, rs2511989 was selected as the haplotype-tagging SNP; rs2511989 was reported to be associated with the risk of AMD in previous studies [16], [19] (Fig. 1). Details of allele and genotype counts and summary statistics for rs2511989 are shown in Table 2. The success rate of genotyping of rs2511989 was 98.1%, and the distributions of the genotypes for all study groups were in the Hardy–Weinberg equilibrium (P>0.05). Although we compared the genotype distributions of rs2511989 in typical AMD and PCV patients against 2 independent control groups (cataract patients without ARM and healthy Japanese individuals), SERPING1 rs2511989 was not significantly associated with typical AMD (P = 0.932 and 0.513, respectively); furthermore, it was not significantly associated with PCV (P = 0.505 and 0.141, respectively). After correction for age and gender differences based on a logistic regression model, the difference in the genotype distributions remained insignificant (P>0.05). Table 3 shows the odds ratios adjusted for age and gender under various genetic models. We could not find a significant association in any genetic model.
Table 1

Characteristics of the Study Population.

CasesControls
tAMDPCVControl 1* Control 2
No. of participants4015103361194
AgeMean ± SD77.38±8.3974.98±7.7774.16±8.4250.34±15.9
GenderMen287372142493
Women114138194701

tAMD, typical age-related macular degeneration; PCV, polypoidal choroidal vasculopathy; SD, standard deviation.

*Cataract patients without age-related maculopathy.

†Healthy Japanese individuals.

Figure 1

Linkage disequilibrium (LD) structure across the complement component 1 inhibitor (SERPING1) gene in Caucasian and Japanese populations.

Genotype data were retrieved from HapMap CEU (Utah residents with ancestry from northern and western Europe; A) and JPT (Japanese in Tokyo, Japan; B) data sets. Haplotype blocks were determined using the “four-gamete rule” option in Haploview; all HapMap single nucleotide polymorphisms on SERPING1 gene are in the same block in both populations. Each box provides estimated statistics of the coefficient of determination (r2), with darker shades representing stronger LD.

Table 2

SERPING1 rs2511989 Genotypic Distributions and Results of Association Tests and Power Analysis.

vs Control 1vs Control 2
GGGAAAMAFP ValueAdjusted P* Power P ValueAdjusted P* Power
CasestAMD29310260.1420.9320.68793.6%0.5130.86099.3%
PCV38012550.1320.5050.85595.7%0.1410.67899.2%
ControlsControl 124876100.144------
Control 2859308270.152------

tAMD, typical age-related macular degeneration; PCV, polypoidal choroidal vasculopathy; MAF, minor allele frequency.

*Adjusted for age and gender.

†Statistical power for detecting the association reported in the previous study (odds ratio 0.63).

Table 3

Odds Ratios in Various Genetic Models.

Adjusted Odds Ratio (95% Confidence Interval)*
GroupModelvs tAMDvs PCV
Control 1Additive0.938 (0.687–1.281)0.972 (0.72–1.312)
Dominant1.283 (0.746–2.204)0.598 (0.338–1.056)
Recessive0.934 (0.783–1.114)1.283 (0.746–2.204)
Control 2Additive1.034 (0.716–1.491)0.933 (0.673–1.294)
Dominant0.940 (0.470–1.879)0.709 (0.349–1.440)
Recessive1.025 (0.839–1.254)0.983 (0.823–1.174)

*Adjusted for age and gender.

tAMD, typical age-related macular degeneration; PCV, polypoidal choroidal vasculopathy.

Linkage disequilibrium (LD) structure across the complement component 1 inhibitor (SERPING1) gene in Caucasian and Japanese populations.

Genotype data were retrieved from HapMap CEU (Utah residents with ancestry from northern and western Europe; A) and JPT (Japanese in Tokyo, Japan; B) data sets. Haplotype blocks were determined using the “four-gamete rule” option in Haploview; all HapMap single nucleotide polymorphisms on SERPING1 gene are in the same block in both populations. Each box provides estimated statistics of the coefficient of determination (r2), with darker shades representing stronger LD. tAMD, typical age-related macular degeneration; PCV, polypoidal choroidal vasculopathy; SD, standard deviation. *Cataract patients without age-related maculopathy. †Healthy Japanese individuals. tAMD, typical age-related macular degeneration; PCV, polypoidal choroidal vasculopathy; MAF, minor allele frequency. *Adjusted for age and gender. †Statistical power for detecting the association reported in the previous study (odds ratio 0.63). *Adjusted for age and gender. tAMD, typical age-related macular degeneration; PCV, polypoidal choroidal vasculopathy. Next, we calculated our statistical power to detect an association of a risk allele with the odds ratio reported in the previous study that investigated the association of rs2511989 with developing AMD. When we targeted the original study reported by Ennis (odds ratio 0.63) [16], our sample size had more than 90% power to detect the association (Table 2). In addition, the statistical power calculation revealed that our sample size could detect the gene-disease association for an odds ratio of 0.797 by more than 80%.

Discussion

In the present study, we investigated whether SERPING1 gene variants are associated with typical AMD or with PCV in a Japanese population. We selected rs2511989 as the haplotype-tagging SNP, because this has been reported to be positively associated with the risk of AMD in Caucasians. The results of this study showed that SERPING1 rs2511989 was not associated with the risk for typical AMD in a Japanese population; thus, the results did not support the hypothesis that an association between the SERPING1 gene and AMD exists. Our sample size had more than 90% power to detect the association determined in the previous study in a Caucasian cohort (odds ratio 0.63) [16]. Furthermore, we found no evidence to support the role played by SERPING1 rs2511989 in the susceptibility to PCV, and this finding is in agreement with that of the previous study in a Chinese population [21]. The reported association between AMD and SERPING1 rs2511989 is shown in Table 4. The size of our Japanese cohort was similar to that of the original study [16]. Furthermore, the statistical power calculation revealed that our sample size could detect the gene-disease association for an odds ratio of 0.797 by more than 80%. Had there been a true protective effect of SERPING1 gene variants for developing AMD at the same level as was reported in previous studies [16], [19], the statistical power of our study would have detected such an association. Differences in the ethnicities of subjects might be 1 reason for the difference observed between the results of this study in a Japanese cohort and those of the previous study in a Caucasian cohort. Frequency of the minor allele of rs2511989 was reportedly greater in the earlier study in a Caucasian population than that of the present study in a Japanese population. In fact, in reference to the allele frequency data from the HapMap, all genetic variants across the SERPING1 gene showed smaller minor allele frequency in Japanese than in Caucasians.
Table 4

Comparison of Association Observed between AMD and SERPING1 rs2511989.

Subject GroupCurrent Study (JP)Mayo Subjects (US)AREDS Subjects (US)Ennis et al. (UK)Ennis et al. (US)Lee et al. (US)Lu et al. (CH)
SubjectsCaseControl 1Control 2CaseControlCaseControlCaseControlCaseControlCaseControlCaseControl
No. of participants40133611944703101221295479479248252556256194285
Allele countG68857220265693631435357597500322282669283336493
A1149636237125710072333554541742224132295269
Genotype countGG2932488591791034361151911321007921374147215
GA102763082111575631272152361221242731354263
AA61027805022253701092649704753
MAF0.1420.1440.1520.3950.4150.4120.3950.3730.4750.3510.4410.3820.4470.1340.123
P values-0.9320.513-0.46-0.41-5.4×10−6 -0.0037-0.011-0.61

MAF, minor allele frequency.

MAF, minor allele frequency. Another possible explanation for the differences between our findings and those of other studies in different ethnic cohorts may include a difference in the phenotypes of AMD. Numerous studies have reported that distinguishing features of Asian AMD include male predominance, unilateral presentation, comparatively low incidence of soft drusen, and greater prevalence of neovascular AMD and PCV [26]–[29]. To address these concerns, we classified AMD patients into those with typical AMD and those with PCV, but the possible hidden differences in the phenotypes cannot be excluded. Alternatively, considering the fact that genetic variants that are associated with a particular disease in 1 population may not necessarily be associated in another population [30]–[32]; moreover, it is possible that gene-disease association of SERPING1 in populations from East Asia is very weak or absent as compared with Caucasian populations. In this study, we used general population-based controls (Control 2). The possibility exists that some of the eyes in the control 2 group might have or develop AMD or PCV, and this might be a possible explanation for the negative results in this study. However, because the prevalence of AMD in the general population is estimated to be 0.5% in the Japanese population [33], the loss of the statistical power of association analysis must be negligible. In addition, we also performed a subset analysis on controls 2 with 55 years of age or older to minimize the possibility that some of the eyes in the control group might develop AMD or PCV. However, no new significant differences in the genotypic distributions were found in the current study (data not shown). Thus, we concluded that the result of the analysis using control 2 is valuable as reference data which supports a lack of association between SERPING1 and both typical AMD and PCV in a Japanese population. Another limitation is about geographical difference of Control 1, which may influence genetic background of the participants. However, because the Japanese population has been reported to have a rather small genetic diversity, according to data from the SNP discovery project in Japan [34], geographical difference should not be affect our statistical results. In conclusion, this study showed a lack of association between SERPING1 and both typical AMD and PCV in a Japanese population; thus, the results suggest that SERPING1 does not play a significant role in the risk of developing AMD or PCV in Japanese.
  34 in total

1.  Sample size requirements for matched case-control studies of gene-environment interaction.

Authors:  W James Gauderman
Journal:  Stat Med       Date:  2002-01-15       Impact factor: 2.373

2.  Gene-based SNP discovery as part of the Japanese Millennium Genome Project: identification of 190,562 genetic variations in the human genome. Single-nucleotide polymorphism.

Authors:  Hisanori Haga; Ryo Yamada; Yozo Ohnishi; Yusuke Nakamura; Toshihiro Tanaka
Journal:  J Hum Genet       Date:  2002       Impact factor: 3.172

3.  The International HapMap Project.

Authors: 
Journal:  Nature       Date:  2003-12-18       Impact factor: 49.962

4.  The Bowman lecture. Towards an understanding of age-related macular disease.

Authors:  A C Bird
Journal:  Eye (Lond)       Date:  2003-05       Impact factor: 3.775

5.  Haploview: analysis and visualization of LD and haplotype maps.

Authors:  J C Barrett; B Fry; J Maller; M J Daly
Journal:  Bioinformatics       Date:  2004-08-05       Impact factor: 6.937

6.  Complement factor H variant increases the risk of age-related macular degeneration.

Authors:  Jonathan L Haines; Michael A Hauser; Silke Schmidt; William K Scott; Lana M Olson; Paul Gallins; Kylee L Spencer; Shu Ying Kwan; Maher Noureddine; John R Gilbert; Nathalie Schnetz-Boutaud; Anita Agarwal; Eric A Postel; Margaret A Pericak-Vance
Journal:  Science       Date:  2005-03-10       Impact factor: 47.728

7.  The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study.

Authors:  R Klein; B E Klein; S C Jensen; S M Meuer
Journal:  Ophthalmology       Date:  1997-01       Impact factor: 12.079

8.  Age-related macular degeneration in Chinese-Canadians.

Authors:  T S Chang; D Hay; P Courtright
Journal:  Can J Ophthalmol       Date:  1999-08       Impact factor: 1.882

9.  Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics.

Authors:  Kenichiro Sho; Kanji Takahashi; Haruhiko Yamada; Mitsumasa Wada; Yoshimi Nagai; Tsuyoshi Otsuji; Maki Nishikawa; Yumiko Mitsuma; Yukari Yamazaki; Miyo Matsumura; Masanobu Uyama
Journal:  Arch Ophthalmol       Date:  2003-10

Review 10.  An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group.

Authors:  A C Bird; N M Bressler; S B Bressler; I H Chisholm; G Coscas; M D Davis; P T de Jong; C C Klaver; B E Klein; R Klein
Journal:  Surv Ophthalmol       Date:  1995 Mar-Apr       Impact factor: 6.048

View more
  15 in total

1.  Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.

Authors:  Yu Kawashima; Akio Oishi; Akitaka Tsujikawa; Kenji Yamashiro; Masahiro Miyake; Naoko Ueda-Arakawa; Munemitsu Yoshikawa; Ayako Takahashi; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-13       Impact factor: 3.117

2.  Association between SERPING1 rs2511989 polymorphism and age-related macular degeneration: Meta-analysis.

Authors:  Yi Dong; Ze-Dong Li; Xin-Yu Fang; Xue-Feng Shi; Song Chen; Xin Tang
Journal:  Int J Ophthalmol       Date:  2015-04-18       Impact factor: 1.779

3.  Genetic risk, ethnic variations and pharmacogenetic biomarkers in age-related macular degeneration and polypoidal choroidal vasculopathy.

Authors:  Jane Z Kuo; Tien Y Wong; Frank S Ong
Journal:  Expert Rev Ophthalmol       Date:  2013-04-01

4.  Genome-wide association study of colorectal cancer identifies six new susceptibility loci.

Authors:  Fredrick R Schumacher; Stephanie L Schmit; Shuo Jiao; Christopher K Edlund; Hansong Wang; Ben Zhang; Li Hsu; Shu-Chen Huang; Christopher P Fischer; John F Harju; Gregory E Idos; Flavio Lejbkowicz; Frank J Manion; Kevin McDonnell; Caroline E McNeil; Marilena Melas; Hedy S Rennert; Wei Shi; Duncan C Thomas; David J Van Den Berg; Carolyn M Hutter; Aaron K Aragaki; Katja Butterbach; Bette J Caan; Christopher S Carlson; Stephen J Chanock; Keith R Curtis; Charles S Fuchs; Manish Gala; Edward L Giovannucci; Stephanie M Gogarten; Richard B Hayes; Brian Henderson; David J Hunter; Rebecca D Jackson; Laurence N Kolonel; Charles Kooperberg; Sébastien Küry; Andrea LaCroix; Cathy C Laurie; Cecelia A Laurie; Mathieu Lemire; David Levine; Jing Ma; Karen W Makar; Conghui Qu; Darin Taverna; Cornelia M Ulrich; Kana Wu; Suminori Kono; Dee W West; Sonja I Berndt; Stéphane Bezieau; Hermann Brenner; Peter T Campbell; Andrew T Chan; Jenny Chang-Claude; Gerhard A Coetzee; David V Conti; David Duggan; Jane C Figueiredo; Barbara K Fortini; Steven J Gallinger; W James Gauderman; Graham Giles; Roger Green; Robert Haile; Tabitha A Harrison; Michael Hoffmeister; John L Hopper; Thomas J Hudson; Eric Jacobs; Motoki Iwasaki; Sun Ha Jee; Mark Jenkins; Wei-Hua Jia; Amit Joshi; Li Li; Noralene M Lindor; Keitaro Matsuo; Victor Moreno; Bhramar Mukherjee; Polly A Newcomb; John D Potter; Leon Raskin; Gad Rennert; Stephanie Rosse; Gianluca Severi; Robert E Schoen; Daniela Seminara; Xiao-Ou Shu; Martha L Slattery; Shoichiro Tsugane; Emily White; Yong-Bing Xiang; Brent W Zanke; Wei Zheng; Loic Le Marchand; Graham Casey; Stephen B Gruber; Ulrike Peters
Journal:  Nat Commun       Date:  2015-07-07       Impact factor: 14.919

Review 5.  Genetics of Hereditary Angioedema Revisited.

Authors:  Anastasios E Germenis; Matthaios Speletas
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

6.  Update on the role of genetics in the onset of age-related macular degeneration.

Authors:  Peter James Francis; Michael L Klein
Journal:  Clin Ophthalmol       Date:  2011-08-15

7.  Genome-wide association study identifies a new SMAD7 risk variant associated with colorectal cancer risk in East Asians.

Authors:  Ben Zhang; Wei-Hua Jia; Keitaro Matsuo; Aesun Shin; Yong-Bing Xiang; Koichi Matsuda; Sun Ha Jee; Dong-Hyun Kim; Peh Yean Cheah; Zefang Ren; Qiuyin Cai; Jirong Long; Jiajun Shi; Wanqing Wen; Gong Yang; Bu-Tian Ji; Zhi-Zhong Pan; Fumihiko Matsuda; Yu-Tang Gao; Jae Hwan Oh; Yoon-Ok Ahn; Michiaki Kubo; Lai Fun Thean; Eun Jung Park; Hong-Lan Li; Ji Won Park; Jaeseong Jo; Jin-Young Jeong; Satoyo Hosono; Yusuke Nakamura; Xiao-Ou Shu; Yi-Xin Zeng; Wei Zheng
Journal:  Int J Cancer       Date:  2014-01-29       Impact factor: 7.396

8.  Positive association of CD36 gene variants with the visual outcome of photodynamic therapy in polypoidal choroidal vasculopathy.

Authors:  Shigeru Honda; Hiroaki Bessho; Naoshi Kondo; Sentaro Kusuhara; Yasutomo Tsukahara; Akira Negi
Journal:  Mol Vis       Date:  2012-11-22       Impact factor: 2.367

Review 9.  Mechanism of inflammation in age-related macular degeneration.

Authors:  Francesco Parmeggiani; Mario R Romano; Ciro Costagliola; Francesco Semeraro; Carlo Incorvaia; Sergio D'Angelo; Paolo Perri; Paolo De Palma; Katia De Nadai; Adolfo Sebastiani
Journal:  Mediators Inflamm       Date:  2012-11-07       Impact factor: 4.711

10.  Genome-wide association analyses in East Asians identify new susceptibility loci for colorectal cancer.

Authors:  Wei-Hua Jia; Ben Zhang; Keitaro Matsuo; Aesun Shin; Yong-Bing Xiang; Sun Ha Jee; Dong-Hyun Kim; Zefang Ren; Qiuyin Cai; Jirong Long; Jiajun Shi; Wanqing Wen; Gong Yang; Ryan J Delahanty; Bu-Tian Ji; Zhi-Zhong Pan; Fumihiko Matsuda; Yu-Tang Gao; Jae Hwan Oh; Yoon-Ok Ahn; Eun Jung Park; Hong-Lan Li; Ji Won Park; Jaeseong Jo; Jin-Young Jeong; Satoyo Hosono; Graham Casey; Ulrike Peters; Xiao-Ou Shu; Yi-Xin Zeng; Wei Zheng
Journal:  Nat Genet       Date:  2012-12-23       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.